Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Considerable default risk
Profitability factor
Greatly overvalued vs peers
Very low or no dividends
Very poor margins and returns
Risk / Profitability
Risk: High
Profitability: Modest
Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Considerable default risk
Profitability factor
Greatly overvalued vs peers
Very low or no dividends
Very poor margins and returns
$ 38.95
About
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for...
About
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the...
